P096 Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease

Shaoul, Ron; Turner, Dan; Sładek, Małgorzata; Veres, G.; Veerman-Wauters, G.; Escher, J.C.; Pærregaard, Anders; Dias, J. Amil; Lionetti, P.; Levine, A.

doi:10.1016/s1873-9946(12)60116-0

Cited by 11 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Were this to apply, it is likely that the relative importance of sensitivity over specificity would increase compared with the current modelling approach. We note that in the study by Shaoul et al 92 two cases had fistulae at diagnosis.…”

Section: Summary Of Modelling Approachmentioning

confidence: 48%

See 1 more Smart Citation

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Waugh

Cummins²,

Royle³

et al. 2013

Health Technology Assessment

235

201

View full text Add to dashboard Cite

Section: Summary Of Modelling Approachmentioning

confidence: 48%

“…Shaoul et al 92 (not included in our meta-analysis) provide a report on calprotectin levels in children (age range 8-17 years) with untreated CD (a case series with no non-IBD comparison group, hence an exclusion for our purposes). The title of their paper is 'limitations of FC' but this appears to be chosen for two reasons.…”

Section: Specificity (95% Ci)mentioning

confidence: 99%

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Waugh

Cummins²,

Royle³

et al. 2013

Health Technology Assessment

235

201

View full text Add to dashboard Cite

“…Some of the authors postulate that the correlation between fecal calprotectin concentration and the activity of the disease is stronger in the case of UC than in CD, which is linked with a rare involvement of the large intestine and with a lack of a complete mucosal healing even in remission phase [7,23,25]. Others have obtained similar fecal calprotectin concentration in both diseases [12,15,26,28] or directed attention to the strong correlation between the activity disease in patients with CD [13,29]. Kosiara and Komraus [14,27] have observed lower average concentration of fecal calprotectin in patients with CD; however, other authors have noted in patients in remission higher content of fecal calprotectin in patients with CD [12,20,26].…”

Section: Discussionmentioning

confidence: 99%

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Krzesiek¹

2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Children constitute 20% of patients with inflammatory bowel diseases (IBD). Still there is a search for a perfect marker for this group of patients which would help in the diagnosis of the disease, in determinating its activity and in monitoring the treatment. Objectives. Evaluate the usefulness of the application of calprotectin measurement in stool samples from children with IBD, as a marker of the severity of inflammation. Material and Methods. We analysed 156 patients: 58 with ulcerative colitis (UC), 67 with Crohn's disease (CD), and 31 from the control group. In all patients the concentration of calprotectin in the sample of feces, markers of inflammation and hemoglobin were measured. Results. Concentration of calprotectin in feces of patients with IBD was above the normal range in all patients with moderate and severe disease and in the majority with mild disease or in remission, but it was normal in all patients from the control group. Conclusions. Elevated concentration of fecal calprotectin (FC) was observed in the majority of patients with IBD, but in none from the control group. The number of patients with elevated FC concentration increased together with the disease activity. FC concentration was higher in patients with severe and moderate disease activity. FC concentration in patients with IBD was associated with the increase of inflammatory markers and decreased haemoglobin. Percentage of laboratory abnormalities in children with Crohn's disease and perianal changes was higher. FC concentration can be a noninvasive marker of disease activity in IBD (Adv Clin Exp Med 2015, 24, 5, 815-822).

show abstract

“…In a recent prospective study FC was elevated at diagnosis in 95% of 60 unselected pediatric patients with CD whereas only 86% of the patients had an increased CRP and 83% an elevated ESR (58). The combination of any 2 of these 3 markers had higher sensitivity (58)(59)(60)(61); in 1 series, 15% of 48 incident IBD cases had no elevation of any of 5 blood markers (hemoglobin, white cell count, platelet count, ESR, and CRP) yet had abnormally raised FC (62). FC levels at diagnosis of pediatric IBD are superior to blood markers as a diagnostic marker for intestinal inflammation, and discriminate IBD from other extraintestinal inflammatory conditions as well as intestinal noninflammatory conditions.…”

Section: Practice Pointsmentioning

confidence: 93%

“…Both markers are excellent tools for identifying the presence of intestinal inflammation with high sensitivity (56,57). In a recent prospective study FC was elevated at diagnosis in 95% of 60 unselected pediatric patients with CD whereas only 86% of the patients had an increased CRP and 83% an elevated ESR (58). The combination of any 2 of these 3 markers had higher sensitivity (58)(59)(60)(61); in 1 series, 15% of 48 incident IBD cases had no elevation of any of 5 blood markers (hemoglobin, white cell count, platelet count, ESR, and CRP) yet had abnormally raised FC (62).…”

Section: Practice Pointsmentioning

confidence: 99%

ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents

Levine

Koletzko

Turner

et al. 2014

J. pediatr. gastroenterol. nutr.

1,058

787

View full text Add to dashboard Cite

Background: The diagnosis of pediatric-onset inflammatory bowel disease (PIBD) can be challenging in choosing the most informative diagnostic tests and correctly classifying PIBD into its different subtypes. Recent advances in our understanding of the natural history and phenotype of PIBD, increasing availability of serological and fecal biomarkers, and the emergence of novel endoscopic and imaging technologies taken together have made the previous Porto criteria for the diagnosis of PIBD obsolete. Methods: We aimed to revise the original Porto criteria using an evidencebased approach and consensus process to yield specific practice recommendations for the diagnosis of PIBD. These revised criteria are based on the Paris classification of PIBD and the original Porto criteria while

show abstract

P096 Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease

Cited by 11 publications

References 0 publications

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents

Contact Info

Product

Resources

About